Posted by Michael Wonder on 18 Aug 2022
CSL Vifor plans UK launch after NICE backs rare disease drug Tavneos
18 August 2022 - UK cost-effectiveness organisation NICE has recommended routine NHS use of a recently approved therapy for two forms of ANCA-associated vasculitis – oral complement C5 inhibitor Tavneos – which will be launched in the next few weeks.
CSL Vifor – which licenses Tavneos (avacopan) from US biotech ChemoCentryx – announced the decision on behalf Vifor Fresenius Medical Care Renal Pharma, its joint venture with Fresenius, which will market the drug in the UK.
